Enlitic, Inc.

Keith Lui

Kevin Lyman

Li Yao

Anthony Upton

Ben Covington

Eric C Poblenz

A medical scan quality assurance system is operable to utilize artificial intelligence to train at least one computer vision model based on a training set of medical scans. A set of medical scans are received. Quality assurance data is generated for the set of medical scans utilizing artificial intelligence by performing at least one quality assurance function on the set of medical scans by utilizing the at least one computer vision model. A first medical scan is identified in the set of medical scans to include an artifact, detected by performing the at least one quality assurance function, that is determined to obscure at least a threshold percentage of a key anatomical part based on the quality assurance data. An artifact obstruction notification indicating the first medical scan is generated for transmission to a client device for display.

Artifact detection via a medical scan quality assurance system

An automatic patient recruitment system is operable generate abnormality data for medical scans by performing at least one inference function on image data of each medical scans by utilizing a computer vision model trained on a training set of medical scans. A subset of a plurality of patients is identified to be eligible for a pharmaceutical study by identifying medical scans having abnormality data that compares favorably to abnormality criteria of the pharmaceutical study. A size of the subset is compared to a minimum participant count requirement. A notification indicating the subset of the plurality of patients is transmitted based on the size of the subset comparing favorably to the minimum participant count requirement.

Automatic patient recruitment system and methods for use therewith

A method includes generating a longitudinal lesion model by performing a training step on a plurality of sets of longitudinal data. Dates of medical scans of different ones of the plurality of sets of longitudinal data have relative time differences corresponding to different time spans, and each set of the plurality of sets of longitudinal data corresponds to one of a plurality of different patients. The longitudinal lesion model is utilized to perform an inference step on a received medical scan to generate, for a lesion detected in the received medical scan, a plurality of lesion change prediction data for a corresponding plurality of different projected time spans ending after the current date. At least one of the plurality of lesion change prediction data is transmitted for display.

Generating lesion change prediction data for medical scans

A clinical trial re-evaluation system is operable to perform at least one assessment function on a set of medical scans for each of a first subset of a set of patients of a failed clinical trial to generate automated assessment data for each of the first subset of the set of patients. The first subset of the set of patients corresponds to a subset of human assessment data determined to have failed to meet criteria of the clinical trial. Patient re-evaluation data is generated for each of the first subset of the set of patients by comparing the automated assessment data to the criteria. The patient re-evaluation data for a second subset of the first subset of the set of patients indicates the automated assessment data passes the criteria. Trial re-evaluation data is generated based on the patient re-evaluation data for transmission to a computing device for display.

Clinical trial re-evaluation system

A lesion tracking system is operable to receive a first medical scan and second medical scan associated with a patient ID. A lesion area calculation is performed on a first subset of image slices determined to include a lesion detected in the first medical to generate a first set of lesion area measurements. The lesion area calculation is performed on a second subset of image slices determined to include the lesion in the second medical scan to generate a second set of lesion area measurements. A lesion volume calculation is performed on the first set of lesion area measurements and the second set of lesion area measurements to generate a first lesion volume measurement and a second lesion volume measurement, respectively, and the first and second lesion volume measurements are utilized to calculate a lesion volume change for transmission to a client device for display via a display device.

Lesion tracking system

A longitudinal data quality assurance system is operable to receive a set of medical scans corresponding to a same first patient. A first chronologically ordered list of the set of medical scans is generated based on a corresponding first set of dates, where each of the corresponding first set of dates are extracted from a headers of the set of medical scans. Quality assurance data is generated for the first chronologically ordered list by performing at least one quality assurance function on at least one of the set of medical scans. A second chronologically ordered list that includes a first subset of the first set of medical scans is generated to rectify at least one continuity error of the first chronologically ordered list, indicated in the quality assurance data. The second chronologically ordered list is transmitted to a client device for display via a display device.

Longitudinal data quality assurance system

An automatic patient recruitment system is operable to determine a set of eligibility criteria, which includes abnormality criteria and other patient criteria, for each of a plurality of pharmaceutical studies. Abnormality data is generated for received medical scans by performing at least one inference function on image data of each medical scans by utilizing a computer vision model trained on a training set of medical scans. One of a plurality of patients is identified to be eligible for a pharmaceutical study by determining a medical scan of the patient has abnormality data that compares favorably to the abnormality criteria of the pharmaceutical study and by determining that the patient has patient data that compares favorably to the other patient criteria of the pharmaceutical study. A notification indicating the identified patient is eligible for the pharmaceutical study is generated for transmission to a client device.

Growing community of inventors

San Francisco, CA, United States of America

Keith Lui